A Study to Assess the Short-Term Efficacy and Safety of Olanzapine and Fluoxetine Compared to Placebo and Fluoxetine for Nonpsychotic Treatment-Resistant Depression

Trial Profile

A Study to Assess the Short-Term Efficacy and Safety of Olanzapine and Fluoxetine Compared to Placebo and Fluoxetine for Nonpsychotic Treatment-Resistant Depression

Discontinued
Phase of Trial: Phase III

Latest Information Update: 26 Aug 2017

At a glance

  • Drugs Fluoxetine (Primary) ; Olanzapine (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 05 Feb 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 11 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 22 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Nov 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top